Cytori to Present at Regen Med Investor Day 2013 on April 17 Business Wire SAN DIEGO -- April 10, 2013 Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that President Marc Hedrick, MD will present at the 2013 Regen Med Investor Day to be held Wednesday, April 17, 2013 in New York City. In addition to the corporate presentation, Dr. Hedrick will participate on the “Clinical Outlooks in Cardiovascular Disease” panel, alongside Ronnda Bartel, PhD of Aastrom Biosciences, Silviu Itescu, MBBS of Mesoblast Limited, Linda Marban, PhD of Capricor and Leslie Miller, MD of the University of South Florida Heart Institute. Specific details for both events are as follows: Clinical Outlooks in Cytori Event: Cardiovascular Disease Panel Therapeutics Presentation Time: 9:00 AM EST 1:00 PM EST Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading financial firms Burrill & Company, Maxim Group and Piper Jaffray, this flagship event features 16 of the regenerative medicine field’s leading small- and mid-cap companies. In addition, there will be disease indication-focused discussions between key opinion leaders, top analysts and senior executives from the sector and keynote-style talks by Jeff Jonas, President of Shire Regenerative Medicine and Kieran Murphy, President and CEO, GE Healthcare Life Sciences. A live video webcast of the panels and company presentations will be available at: http://alliancerm.org/rmdaywebcast and will also be published on ARM’s website shortly after the event. Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at email@example.com. About Cytori Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Our scientific data suggest ADRCs improve blood flow, moderate the inflammatory response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® System product family. www.cytori.com Contact: Cytori Therapeutics Megan McCormick firstname.lastname@example.org +1.858.875.5279
Cytori to Present at Regen Med Investor Day 2013 on April 17
Press spacebar to pause and continue. Press esc to stop.